A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Anchorage, Alaska 99503, United States
Capital Federal, Buenos Aires 1426, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
Ciudad Autónoma de BuenosAires, Buenos Aires C1280AEB, Argentina
Wilton, CORK 0, Ireland
Hamamatasu, Shizuoka 431-3192, Japan
Bunkyo-ku, Tokyo 1138603, Japan
Shinjuku-Ku, Tokyo 1608582, Japan
Shinjuku-ku, Tokyo 1628666, Japan
Df, Mexico City 06720, Mexico
Maastrict, 6229 HX, Netherlands
Timisoara, Timis, 300239, Romania
Badalona-barcelona, 08916, Spain